2019 Wendy and Emery Reves International Breast Cancer Symposium

Join the Harold C. Simmons Comprehensive Cancer Center on September 20-21, 2019, for the Wendy & Emery Reves International Breast Cancer Symposium.

The Reves Symposium is a premier event at UT Southwestern whose objectives are to review the recent progress in breast cancer research and improvements in the clinical care of patients with breast cancer. The Reves Symposium provides information on the latest laboratory-based translational discoveries and new technologies, while exploring developments in treatment options, clinical trials, and population sciences.

Reves Symposium attendees include breast cancer providers and nursing professionals, basic and translational scientists, physician-scientists, clinical trialists, laboratory-based postdoctoral and clinical fellows, graduate students, patient advocates, and interested individuals from industry and North Texas communities.

CHAIR

Carlos L. Arteaga, M.D.
UT Southwestern Simmons Comprehensive Cancer Center

KEYNOTE SPEAKERS

Carlos Caldas, M.D.
University of Cambridge

Lisa Carey, M.D.
University of North Carolina at Chapel Hill

 

DAY 1

SESSION 1 Tumor Heterogeneity

8:30 – 9:00 a.m.

Nicholas Navin, Ph.D. MD Anderson Cancer Center

Breast cancer evolution: insights from single cell genomics

9:00 – 9:30 a.m.

Kornelia Polyak, M.D., Ph.D. Dana-Farber Cancer Institute/Harvard

Regulators of breast tumor heterogeneity

9:30 – 10:00 a.m.

Charles Swanton, M.D., Ph.D. The Francis Crick Institute, UK

Chromosomal instability and genome plasticity in cancer evolution, immune evasion and metastasis

Keynote Speaker

10:20 – 11:00 a.m.

Lisa Carey, M.D. The University of North Carolina at Chapel Hill

 

SESSION 2 Cancer Risk and Health Disparities

11:00 – 11:30 a.m.

Timothy R. Rebbeck, Ph.D. Dana-Farber Cancer Institute/Harvard

Prediction and prevention of cancer in BRCA1/2 mutation carriers in the precision medicine era

11:30 – Noon

Olufunmilayo (Funmi) Olopade, M.D. University of Chicago Cancer Center

Genomic landscape of breast cancer in diverse populations

 

SESSION 3 Cell Cycle and CDK4/6 inhibitors

1:15 – 1:45 p.m.

Andrew Koff, Ph.D. Memorial Sloan Kettering Cancer Center

Senescence after growth arrest: a mechanism by which CDK4/6 inhibitors can exert their anti-tumor effects

1:45 – 2:15 p.m.

Nicholas C. Turner, M.D., Ph.D. Royal Marsden Hospital, UK

Determinants of response and resistance to CDK4/6 inhibitors in breast cancer

2:15 – 2:45 p.m.

Hope S. Rugo, M.D. University of California, San Francisco

 

SESSION 4 De-escalation of Therapy

3:00 – 3:30 p.m.

Armando Giuliano, M.D. Cedars-Sinai Hospital

ACOSOG Z0011: de-escalation of surgical management

3:30 – 4:00 p.m.

Joseph A. Sparano, M.D. Montefiore Medical Center

4:00 – 4:30 p.m.

Sara M. Tolaney, M.D., M.P.H. Dana-Farber Cancer Institute

 

DAY 2

SESSION 5 Breast Cancer Detection/Imaging

8:00 – 8:30 a.m.

Debra L. Monticciolo, M.D. Baylor Scott & White Medical Center

The science of screening and overdiagnosis

8:30 – 9:00 a.m.

Robert M. Nishikawa, Ph.D. University of Pittsburgh

Who is the better learner: radiologists or artificial intelligence?

Keynote Speaker

9:05 – 9:45 a.m.

Carlos Caldas, M.D. University of Cambridge, UK

The new molecular taxonomy of breast cancer

 

SESSION 6 Steroid Nuclear Receptors

10:05 – 10:35 a.m.

Nikhil Wagle, M.D. Dana-Farber Cancer Institute/Harvard

Resistance to endocrine therapies and CDK4/6 inhibitors in ER+ metastatic breast cancer

10:35 – 11:05 a.m.

W. Lee Kraus, Ph.D. UTSW Simmons Cancer Center

Nuclear receptors. transcriptional enhancers, and gene regulation in breast cancers

 

11:15 – 11:45 a.m.

Rinath Jeselsohn, M.D. Dana-Farber Cancer Institute/Harvard

The activating in ER mutations in endocrine resistance

11:45 a.m. – 12:15 p.m.

Suzanne Conzen, M.D.